{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:12:44Z","timestamp":1793445164644,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1094,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1469-0691.2011.03483.x","type":"journal-article","created":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T17:40:59Z","timestamp":1296582059000},"page":"1868-1874","source":"Crossref","is-referenced-by-count":52,"title":["Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients"],"prefix":"10.1016","volume":"17","author":[{"given":"K.","family":"Bochennek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tramsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lehrnbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2011.03483.x_bib1","doi-asserted-by":"crossref","first-page":"A50","DOI":"10.1055\/s-2001-17502","article-title":"Prevention of fungal infections in children and adolescents with cancer","volume":"213","author":"Groll","year":"2001","journal-title":"Klin Padiatr"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib2","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection\u2010related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft\u2010versus\u2010host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 56","key":"10.1111\/j.1469-0691.2011.03483.x_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2133.1999.00011.x","article-title":"Drug interactions of the newer oral antifungal agents","volume":"141","author":"Katz","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1651-2227.2001.tb03257.x","article-title":"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies","volume":"90","author":"Kamaluddin","year":"2001","journal-title":"Acta Paediatr"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-2008-1043890","article-title":"Lipid formulations of amphotericin\u00a0B: clinical perspectives for the management of invasive fungal infections in children with cancer","volume":"210","author":"Groll","year":"1998","journal-title":"Klin Padiatr"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib8","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler\u2010Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High\u2010dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib10","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1128\/AAC.00425-10","article-title":"Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin\u00a0B, and the combination of both in allogeneic hematopoietic stem cell recipients","volume":"54","author":"Groll","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib11","author":"Institute NC"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low\u2010dose liposomal amphotericin\u00a0B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single\u2010center trial","volume":"18","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1439-0507.2001.00706.x","article-title":"Liposomal amphotericin\u00a0B for prophylaxis of invasive fungal infections in high\u2010risk paediatric patients with chemotherapy\u2010related neutropenia: interim analysis of a prospective study","volume":"44","author":"Uhlenbrock","year":"2001","journal-title":"Mycoses"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00520-006-0125-7","article-title":"Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants","volume":"15","author":"Simon","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jac\/dkm521","article-title":"Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients","volume":"61","author":"Allinson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib18","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.ejca.2008.06.022","article-title":"Compliance with anti\u2010infective preventive measures: a multicentre survey among paediatric oncology patients","volume":"44","author":"Lehrnbecher","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double\u2010blind, multicenter study of caspofungin versus liposomal amphotericin\u00a0B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib20","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin\u00a0B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double\u2010blind, placebo\u2010controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001432-200412000-00005","article-title":"Clinical utility of antifungal pharmacokinetics and pharmacodynamics","volume":"17","author":"Andes","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-3046.2006.00643.x","article-title":"Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy","volume":"11","author":"Grigull","year":"2007","journal-title":"Pediatr Transplant"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2011.03483.x_bib25","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1086\/421959","article-title":"Issues in clinical trials of prophylaxis of fungal infections","volume":"39","author":"Powers","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl. 1","key":"10.1111\/j.1469-0691.2011.03483.x_bib26","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1080\/13693780802247694","article-title":"Nosocomial aspergillosis and building construction","volume":"47","author":"Haiduven","year":"2009","journal-title":"Med Mycol"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/sj.leu.2403922","article-title":"Common genetic variants in the interleukin\u20106 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia","volume":"19","author":"Lehrnbecher","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10875-008-9197-0","article-title":"IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C\u2010reactive protein level","volume":"28","author":"Sainz","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1111\/j.1469-0691.2011.03483.x_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000110070","article-title":"Cost\u2013benefit assessment of antifungal prophylaxis with liposomal amphotericin\u00a0B in neutropenic patients","volume":"30","author":"Penack","year":"2007","journal-title":"Onkologie"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14619352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14619352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T08:13:39Z","timestamp":1559981619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14619352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1198743X14619352"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03483.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}